Get the Stockscreener App
0.6951
2.76%
0.0187
After Hours:
.70
0.0049
+0.70%
Xilio Therapeutics Inc stock is traded at $0.6951, with a volume of 604.73K.
It is up +2.76% in the last 24 hours and down -4.81% over the past month.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.
See More
Previous Close:
$0.6764
Open:
$0.6764
24h Volume:
604.73K
Relative Volume:
1.02
Market Cap:
$46.95M
Revenue:
-
Net Income/Loss:
$-81.22M
P/E Ratio:
-0.2348
EPS:
-2.96
Net Cash Flow:
$-74.41M
1W Performance:
+6.89%
1M Performance:
-4.81%
6M Performance:
-0.42%
1Y Performance:
-31.18%
1-Day Range:
$0.6752
$0.7161
1-Week Range:
$0.632
$0.7161
52-Week Range:
$0.615
$1.70
Xilio Therapeutics Inc Stock (XLO) Company Profile
Name
Xilio Therapeutics Inc
Sector
Industry
Phone
617-833-1027
Address
828 WINTER STREET, WALTHAM
Compare XLO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XLO
Xilio Therapeutics Inc
|
0.6951 | 45.68M | 0 | -81.22M | -74.41M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Xilio Therapeutics Inc Stock (XLO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-25 | Initiated | Leerink Partners | Outperform |
| Dec-21-22 | Initiated | Chardan Capital Markets | Buy |
| Jan-10-22 | Initiated | H.C. Wainwright | Buy |
| Nov-16-21 | Initiated | Cowen | Outperform |
| Nov-16-21 | Initiated | Guggenheim | Buy |
| Nov-16-21 | Initiated | Morgan Stanley | Overweight |
| Nov-16-21 | Initiated | Raymond James | Outperform |
View All
Xilio Therapeutics Inc Stock (XLO) Latest News
Xilio Therapeutics reports $35.8 million in proceeds from Series B warrant exercises - Investing.com Nigeria
Xilio Therapeutics Extends Cash Runway Into 2027 - TipRanks
Xilio Therapeutics, Inc. (NASDAQ:XLO) Sees Large Decrease in Short Interest - Defense World
Xilio Therapeutics (NASDAQ:XLO) Stock Price Down 0.5% – What’s Next? - Defense World
Will Xilio Therapeutics Inc. stock reach all time highs in 20252025 Market Overview & High Accuracy Swing Trade Signals - bolumsonucanavari.com
Can Xilio Therapeutics Inc. stock outperform in 2025 bull marketJuly 2025 PreEarnings & Risk Managed Investment Strategies - Улправда
Is Xilio Therapeutics Inc. stock dividend yield sustainableWeekly Market Report & High Conviction Investment Ideas - Улправда
Is Xilio Therapeutics Inc. stock a defensive play in 2025July 2025 Sector Moves & Free Fast Gain Swing Trade Alerts - Улправда
Loss Report: Can Xilio Therapeutics Inc. stock outperform in 2025 bull marketJuly 2025 EndofMonth & High Win Rate Trade Alerts - Улправда
Why Xilio Therapeutics Inc. stock remains undervaluedJuly 2025 Reactions & High Win Rate Trade Tips - bolumsonucanavari.com
Why Xilio Therapeutics Inc. stock attracts high net worth investorsMarket Sentiment Report & AI Based Buy/Sell Signal Reports - Улправда
Is Xilio Therapeutics Inc. stock supported by strong fundamentalsProfit Target & High Conviction Investment Ideas - Улправда
Xilio Therapeutics Inc (XLO) looking to reclaim success with recent performance - setenews.com
Xilio Therapeutics Inc (XLO) can make a big difference with a little luck - setenews.com
Xilio Therapeutics, Inc. (XLO) -5.65% in After-hours: Slide Amid Routine Trading Conditions - Stocks Telegraph
Is Xilio Therapeutics Inc. stock trading at a premium valuationJuly 2025 Sentiment & Fast Gain Swing Alerts - Newser
Why Xilio Therapeutics Inc. stock is trending among retail traders2025 Price Action Summary & Expert Curated Trade Ideas - Newser
Can Xilio Therapeutics Stock Recover If Markets Fall? - Trefis
Recap Report: Why Xilio Therapeutics Inc. stock attracts high net worth investorsProduct Launch & High Accuracy Investment Signals - moha.gov.vn
Xilio Therapeutics announces pricing of $50 million public offering - MSN
Xilio Therapeutics Approves 2025 Stock Incentive Plan - MSN
[S-8] Xilio Therapeutics, Inc. Employee Benefit Plan Registration | XLO SEC FilingForm S-8 - Stock Titan
[Form 4] Xilio Therapeutics, Inc. Insider Trading Activity - Stock Titan
[8-K] Xilio Therapeutics, Inc. Reports Material Event | XLO SEC FilingForm 8-K - Stock Titan
AbbVie and Xilio partner for tumor-activated therapies - MSN
Xilio Therapeutics, Inc. (XLO) Reports Q3 Loss, Misses Revenue Estimates - MSN
Is Xilio Therapeutics Inc. stock a buy before product launchesJuly 2025 Rallies & Low Drawdown Momentum Ideas - newser.com
How institutional buying supports Xilio Therapeutics Inc. stockMarket Performance Report & High Accuracy Trade Alerts - newser.com
Is Xilio Therapeutics Inc. stock resilient to inflationWeekly Trade Report & Low Risk High Reward Trade Ideas - newser.com
Is Xilio Therapeutics Inc a good long term investmentFundamental Stock Analysis & Free Technical Analysis and Insights - earlytimes.in
Can Samtex Fashions Limited Outperform Index Funds Over the Next 5 YearsEmerging Market Stocks & Free Rapid Profit Acceleration - earlytimes.in
Can GSM Foils Limited Sustain EPS Growth Under Competitive PressureEquity Performance Review & Low Risk Trading Portfolio - earlytimes.in
Is ACRS a good long-term investment? - earlytimes.in
Tick level data insight on Xilio Therapeutics Inc. volatilityGlobal Markets & Stock Timing and Entry Methods - newser.com
How Xilio Therapeutics Inc. stock compares to market leadersWeekly Gains Report & High Accuracy Trade Signal Alerts - newser.com
Why Xilio Therapeutics Inc. stock remains on watchlists2025 Buyback Activity & Fast Gain Swing Alerts - newser.com
Xilio Therapeutics Reports Revenue Growth Amidst Challenges - MSN
Why Xilio Therapeutics Inc. stock is in analyst buy zoneTrade Exit Summary & Verified Entry Point Signals - newser.com
How geopolitical tensions affect Xilio Therapeutics Inc. stock2025 Macro Impact & Daily Stock Momentum Reports - newser.com
Is Xilio Therapeutics Inc. stock safe for conservative investorsJuly 2025 Highlights & Daily Stock Trend Watchlist - newser.com
Is it too late to sell Xilio Therapeutics Inc.2025 Market Trends & AI Forecasted Entry and Exit Points - newser.com
Is it time to cut losses on Xilio Therapeutics Inc.Portfolio Value Report & Daily Technical Stock Forecast Reports - newser.com
Published on: 2025-11-19 00:08:23 - newser.com
Xilio Therapeutics Inc Stock (XLO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Xilio Therapeutics Inc Stock (XLO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Shannon James Samuel | Director |
Jun 17 '25 |
Buy |
0.69 |
25,000 |
17,215 |
70,000 |
| Russo Rene | PRESIDENT AND CEO |
Jun 16 '25 |
Buy |
0.68 |
36,289 |
24,680 |
281,172 |
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):